Exhibit 10.20


 


CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED
FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED.


 


LICENSE
AGREEMENT


 


This
License Agreement (the “Agreement”) is made and entered into effective as of March 12, 2020 (the “Effective
Date”) by and between Tango Therapeutics, Inc. (“Tango”), a corporation organized and existing under the
laws of Delaware, having an address at 100 Binney Street, Suite 700, Cambridge, Massachusetts 02142, and Medivir AB, a Swedish corporation
with corporate address Box 1086, SE-141 22 Huddinge Sweden (“Medivir”). Tango and Medivir are sometimes referred to
herein individually as a “Party” and collectively as the “Parties.”


 


BACKGROUND


 


		A.	Medivir
                                            has a preclinical-stage research program relating to [***] (as further defined below, the
                                            “Target”) and owns certain patents, know-how and other intellectual property
                                            related to such research program.



 


		B.	Tango
                                            desires to obtain an exclusive license to such patents, know-how and other intellectual property
                                            in order to research, develop and commercially exploit products directed to the Target, and
                                            Medivir desires to grant such license to Tango, upon the terms and conditions set forth herein.



 


NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:


 


Article
I

DEFINITIONS


 


For
purposes of this Agreement, the following terms when used with initial capital letters shall have the respective meanings set forth below.


 


1.1 “Affiliate”
of a Person means any other Person which, directly or indirectly through one or more intermediaries, controls, is controlled by, or is
under common control with such first Person, as the case may be. As used in this Section 1.1, “control” means: (a)
to possess, directly or indirectly, the power to affirmatively direct the management and policies of such person, corporation, or other
business entity, whether through ownership of voting securities or by contract relating to voting rights or corporate governance; or
(b) direct or indirect beneficial ownership of fifty percent (50%) or more of the voting share capital in such person, corporation, or
other business entity.


 


1.2 “ANDA”
means an abbreviated new drug application filed pursuant to the requirements of the FDA pursuant to 21 C.F.R. Part 314 to obtain regulatory
approval for a product in the United States, or the equivalent application or filing in another country (as applicable).


 


1.3 “Annual
Net Sales” means the worldwide Net Sales of a particular Licensed Product for the particular calendar year.


 






    - 1 -


     


    

 


1.4 “Candidate
Drug” means a Compound with respect to which Tango, itself or through an Affiliate or Third Party, has completed IND-enabling
GLP toxicology studies.


 


1.5 “Clinical
Trial” means any Phase I Clinical Trial, Phase III Clinical Trial or any other test or study in human subjects.


 


1.6 “Commercially
Reasonable Efforts” means, with respect to the efforts to be expended by a Party in connection with a particular activity or
objective to be conducted under this Agreement, that level of efforts that such Party would normally use for the development or commercialization
of a comparable pharmaceutical product that it is actively developing or commercializing for a similar patient population at a similar
stage of its development or commercialization, taking into account all scientific, commercial, business and other factors that such Party
would reasonably take into account, including issues of safety and efficacy, expected and approved product labeling, expected and actual
cost and time to develop, expected and actual profitability, expected and actual return on investment, expected and actual competitiveness
of Third Party alternative products (including generic products) in the marketplace, the nature and extent of expected and actual market
exclusivity (including Patent coverage and regulatory exclusivity), the expected likelihood of regulatory approval, the expected and
actual pricing and level of reimbursement, and the expected and actual amounts of marketing and promotional expenditures required. Commercially
Reasonable Efforts shall be determined on a country-by-country basis for a Licensed Product and it is anticipated that the level of effort
and resources that constitute “Commercially Reasonable Efforts” with respect to a particular country will change over time,
reflecting changes in the status of a Licensed Product and the country(ies) involved.


 


1.7 “Compound”
means [***].


 


1.8 “Compulsory
License” means, with respect to a Licensed Product in a country or territory, a license, or rights granted to a Third Party
by a governmental agency within such country or territory to sell or offer for sale such Licensed Product in such country or territory.


 


1.9 “Compulsory
Licensee” means a Third Party granted a Compulsory License.


 


1.10 “Control”
or “Controlled” means, with respect to any information, data, materials, know-how or intellectual property right,
that a Party (a) owns or (b) has a license to such information, data, materials, know-how or intellectual property right and, in each
case ((a) and (b)), has the power to grant to the other Party access, a license, or a sublicense (as applicable) to the same on the terms
and conditions set forth in this Agreement without violating any obligations of the granting Party to any Third Party.


 


1.11 “Directed
To” means, with regard to the Target, that any compound, molecule or product: [***]. A product incorporating such compound,
molecule or product shall also be “Directed To” the Target.


 


1.12 “Existing
Agreement” means a contractual arrangement existing at the Effective Date whereby a Third Party is entitled to select and inlicense
rights with respect to certain targets or programmes discovered, developed or inlicensed by Tango, including any contractual arrangement
amending or replacing (in whole or in part) such arrangement after the Effective Date.


 






    - 2 -


     


    

 


1.13 “FDA”
means the United States Food and Drug Administration, or any successor entity thereto performing similar functions.


 


1.14 “Field”
means all uses and applications.


 


1.15 “First
Commercial Sale” means, [***].


 


1.16 “Generic
Version” means, with respect to a particular Licensed Product and a particular country in the Territory, a non-proprietary
product that (a) is identical to such Licensed Product, (b) obtained Marketing Approval by means of an ANDA filing or a similar procedure
for establishing equivalence to such Licensed Product; and (c) is legally marketed in such country by an entity other than a Party or
any of its Affiliates or Sublicensees, or a Third Party that obtained rights to market such product from a Party or any of its Affiliates
or Sublicensees.


 


1.17 “Genetic
Context” means, with respect to a Licensed Product, the molecular genetic profile [***]


 


1.18 “GLP”
means the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, and comparable
regulatory standards promulgated by any other Regulatory Authority applicable to the Territory, as may be updated from time to time,
including applicable quality guidelines promulgated by the International Conference on Harmonization.


 


1.19 “IND”
means an investigational new drug application or similar application filed with a Regulatory Authority in any country or group of countries
prior to beginning Clinical Trials in that country or in that group of countries.


 


1.20 “Licensed
Intellectual Property” means the Licensed Patents and the Licensed Know-How.


 


1.21 “Licensed
Know-How” means all proprietary information, data, materials, know-how and other intellectual property Controlled by Medivir
or any of its Affiliates as of the Effective Date or during the term of this Agreement, that is reasonably related to the Target or is
necessary or useful to make, have made, use, sell, offer for sale, import, or otherwise exploit a Compound or Licensed Product, including
the information, data, materials, know-how and other intellectual property set out on Exhibit 1.21. For clarity, Licensed
Know-How excludes Licensed Patents.


 


1.22 “Licensed
Patents” means all Patents Controlled by Medivir or any of its Affiliates as of the Effective Date or during the term of this
Agreement (including the interest of Medivir or any of its Affiliates in any Patent jointly owned by any such Person with Tango), that
are reasonably necessary or useful to make, have made, use, sell, offer for sale, import, or otherwise exploit a Compound or Licensed
Product. The Licensed Patents include those Patents listed on Exhibit 1.22, all patents issuing from any patent application
listed on Exhibit 1.22 and all additions, divisionals, continuations, continuations-in-part, substitutions, reissues, re-examinations,
extensions, registrations, patent term extensions, supplemental protection certificates, and renewals of any such Patents.


 






    - 3 -


     


    

 


1.23 “Licensed
Product” means a pharmaceutical product containing or incorporating a Compound as an active pharmaceutical ingredient, either
alone or in combination with one or more other active pharmaceutical ingredient(s), in any formulation, dosage form or method of delivery.


 


1.24 “Major
Market” means [***].


 


1.25 “Marketing
Approval” means all approvals, licenses, registrations or authorizations from the relevant Regulatory Authority in a country,
necessary for the manufacture, use, storage, import, marketing and sale of a Licensed Product in such country, including any such pricing
or reimbursement approval.


 


1.26 “Net
Receipts” means all amounts actually received by Tango or any of its Affiliates from any Compulsory Licensee or Settlement
Sublicensee in consideration of the sale of a Licensed Product.


 


1.27 “Net
Sales” means the sales revenues received by Tango, its Affiliates or Sublicensees, from sales of Licensed Products to Third
Party customers, less reasonable, customary and documented deductions for the following items incurred with respect to sales to such
customers:


 


[***]


 


1.28 “Patent(s)”
means any patents and patent applications, together with all additions, divisions, continuations, continuations-in-part, substitutions,
reissues, re-examinations, extensions, registrations, patent term extensions, supplemental protection certificates, and renewals of any
of the foregoing.


 


1.29 “Person”
means any individual, corporation, company, partnership, association, joint-stock company, trust, unincorporated organization or government
or political subdivision thereof.


 


1.30 “Phase
I Clinical Trial” means a human clinical trial of a Licensed Product, the principal purpose of which is a preliminary determination
of safety, tolerability or pharmacokinetics in healthy individuals or patients as further described in 21 C.F.R. §312.21(a), as
amended (including any such clinical study in any country other than the United States).


 


1.31 “Phase
III Clinical Trial” means a human clinical trial of a Licensed Product, the principal purpose of which is to establish safety
and efficacy in patients with the disease being studied, as further described in 21 C.F.R. §312.21(c), as amended (including any
such clinical study in any country other than the United States), which is designed and intended to be of a size and statistical power
sufficient to serve as a pivotal study to support the filing of an application for Marketing Approval for the indication being studied.


 


1.32 “Regulatory
Authority” means the FDA or any regulatory body with similar regulatory authority in any other jurisdiction.


 






    - 4 -


     


    

 


1.33 “Settlement
Sublicensee” means a Third Party that is granted a license or sublicense under a settlement agreement between such Third Party
and Tango, any of its Affiliates, or any of its or their respective licensees or sublicensees, which agreement was entered into in connection
with an ANDA settlement or similar agreement.


 


1.34 “Sublicensee”
means a Third Party to whom Tango grants a sublicense under the Licensed Intellectual Property to develop and commercialize one or more
Licensed Products. “Sublicensee” excludes Compulsory Sublicensees and Settlement Sublicensees.


 


1.35 “Tango
Patent” means a Patent owned by Tango, which is initially filed by Tango with a patent office in the Territory within [***]
after the Effective Date and issues in the name of Tango, to the extent such Patent claims [***], in a Patent that is listed on Exhibit
1.22 as of the Effective Date, to the extent improvement arises from iterative structure activity relationship work carried out
by Tango or its Affiliates (but excluding a Sublicensee pursuant to the Existing Agreement) using the confidential structure of a compound
set forth on Exhibit 1.7 as of the Effective Date, irrespective of whether the improvement is within or outside the scope
of the claims of the Patent listed in Exhibit 1.22, based on the applicable claim(s) of such Patent as they exist on the
Effective Date, but always excluding any compound or invention which Tango can demonstrate with admissible evidence was identified, conceived
or reduced to practice by Tango, an Affiliate or Sublicensee without the use of the Licensed Know-How and the Licensed Patents. [***].


 


1.36 “Target”
means [***]


 


1.37 “Territory”
means [***].


 


1.38 “Third
Party” means any Person, other than Tango, Medivir and their respective Affiliates.


 


1.39 “Valid
Claim” means any claim of a Patent which claims the composition of matter of a Compound and (a) has not been held unpatentable,
invalid or unenforceable by a court or other government agency of competent jurisdiction in a decision from which no appeal can or has
been taken; and (b) which has not been admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise.
Notwithstanding the foregoing, if such a composition of matter claim of a pending patent application within the Licensed Patents or Tango
Patents has not issued as a claim of a patent within [***], such claim shall not be a Valid Claim for the purposes of this Agreement,
unless and until such claim issues as a claim of an issued patent (from and after which time the same shall be deemed a Valid Claim subject
to paragraphs (a) and (b) above). With respect to a Valid Claim of a pending patent application, the phrase to “infringe a Valid
Claim” means to engage in an activity that would infringe such Valid Claim if it were contained in an issued patent.


 


 


1.40 Additional
Definitions. Each of the following terms shall have the meaning described in the corresponding section of this Agreement indicated
below:


 


	Term	 	Section Defined	 	Term	 	Section Defined
	Acquisition	 	12.13	 	Controlling Party	 	8.3(c)
	Agreement	 	Preamble	 	Disclosing Party	 	7.1
	Bankruptcy Code	 	12.12	 	Dispute	 	12.6(a)
	Confidentiality Agreement	 	7.5	 	Effective Date	 	Preamble
	Infringement	 	8.3(a)	 	Indemnitee Information	 	11.3
	Infringement Action	 	8.3(c)	 	Recipient	 	7.1
	JAMS	 	12.6(b)(i)	 	ROFN Notice	 	9.5
	Liabilities	 	11.1	 	Royalty Term	 	5.4(c)
	Medivir	 	Preamble	 	Tango	 	Preamble
	Medivir Indemnitees	 	11.1	 	Tango Indemnitees	 	11.2
	Party / Parties	 	Preamble	 	Top Biopharmaceutical Company	 	2.1(c)
	Proprietary	 	7.1	 	 	 	 




 






    - 5 -


     


    

 


Article
II

GRANT OF LICENSE; EXCLUSIVITY


 


2.1 License.
Medivir hereby grants to Tango an exclusive [***] license under the Licensed Know-How and Licensed Patents to research, develop, make,
have made, use, sell, offer for sale, import and otherwise exploit the Compounds and Licensed Products, in each case, in the Field and
the Territory. Tango shall have the right to grant and authorize sublicenses of the rights granted in this Section 2.1, provided:


 


(a) Tango
shall promptly notify Medivir of the identity of the Sublicensee and provide a synopsis of key terms of such sublicense to the extent
applicable to the rights granted under this Section 2.1; and


 


(b) Tango
shall remain responsible for the compliance of the Sublicensee with relevant terms of this Agreement, and


 


(c) If
a proposed sublicense (other than pursuant to the Existing Agreement or to a Top Biopharmaceutical Company) delegates all or substantially
all development responsibility for Compounds and Licensed Products to the Sublicensee, Tango shall seek the consent of Medivir to such
sublicensing, not to be unreasonably withheld or delayed. “Top Biopharmaceutical Company” means [***].


 


2.2 Exclusivity.
During the term of this Agreement, [***].


 


Article
III

DISCLOSURE OF INFORMATION; SUPPLY OF MATERIALS


 


3.1 Disclosure
of Medivir’s Information and Materials. Promptly following the Effective Date and in any event no later than [***] thereafter,
Medivir shall, and if applicable, shall cause its Affiliates to, transfer to Tango:


 


(a) the
Licensed Know-How in the electronic format requested by Tango, to the extent possible; provided that if, despite exercising diligent
efforts in connection with such transfer of the Licensed Know-How, Medivir is unable to transfer (or have transferred) all of the Licensed
Know-How to Tango within such [***] period, Medivir shall continue to exercise diligent efforts to complete the transfer the Licensed
Know-How to Tango as soon as reasonably practicable; and


 


(b) all
existing supplies of Compounds in Medivir’s or any of its Affiliates’ possession or Control as of the Effective Date and
the reagents, intermediates and constructs itemized on Exhibit 3.1(b).


 






    - 6 -


     


    

 


3.2 Cooperation
and Assistance.


 


(a) If,
following the completion of the transfer of the Licensed Know-How in accordance with Section 3.1 above, Tango identifies specific items
within such Licensed Know-How which were not transferred to Tango, Medivir shall, and if applicable, shall cause its Affiliates to, use
all reasonable efforts to transfer such items to Tango promptly following Tango’s written request for such items.


 


(b) Upon
the reasonable request of Tango, Medivir shall, and if applicable, shall cause its Affiliates to, reasonably cooperate with and assist
Tango as may be necessary or desirable in order to allow Tango to understand the Licensed Know-How and to utilize the Licensed Know-How
for the purposes contemplated in this Agreement. The Parties understand that Medivir has not conducted an active development program
with respect to the Target for more than [***] and that Medivir is not obligated by this Section 3.2(b) to retain any specific personnel
for purposes of assisting Tango in understanding or utilizing the Licensed Know-How.


 


Article
IV

DILIGENCE


 


4.1 Diligence.
Tango, directly or through its Affiliates, Sublicensees or other contractors, shall use Commercially Reasonable Efforts to develop (including
to file for and receive Marketing Approval for) and, following receipt of Marketing Approval therefor, to commercialize at least one
(1) Licensed Product in the United States and at least one Major Market.


 


4.2 Reporting.
Within [***]after [***], Tango will provide Medivir with a written update summarizing the material activities conducted by Tango in the
[***]period with respect to the development and, if applicable, commercialization of Licensed Products, including lead compounds and
Candidate Drugs identified, medicinal chemistry efforts, animal efficacy and toxicity studies and material regulatory filings and interactions.


 


Article
V

PAYMENTS


 


5.1 Up-Front
Payment. In consideration of the licenses and rights granted by Medivir to Tango under this Agreement, Tango shall pay to Medivir
a non-refundable, up-front payment in the amount of [***] within [***] after the Effective Date.


 


 


5.2 Milestone
Payments. In further consideration of the licenses and rights granted by Medivir to Tango under this Agreement, subject to the terms
and conditions of Section 5.3 and to the extent applicable, Tango shall pay to Medivir the following non-refundable milestone payments
up to [***] following the [***] by Tango or any of its Affiliates or Sublicensees with respect to the first Licensed Product to achieve
such event:


 


	 	 	 	Milestone Event	 	Milestone

 Payment for first

 Licensed

 Product in either

 of the first two

 Genetic Contexts	 	Milestone Payment for the

 first Licensed Product in

 the third Genetic Context

 or the second Licensed

 Product in either of the

 first two Genetic Contexts
	 	1	 	 	[***]	 	[***]	 	[***]
	 	2	 	 	[***]	 	[***]	 	[***]
	 	3	 	 	[***]	 	[***]	 	[***]
	 	4	 	 	[***]	 	[***]	 	[***]
	 	5	 	 	[***]	 	[***]	 	[***]
	 	6	 	 	[***]	 	[***]	 	[***]
	 	7	 	 	[***]	 	[***]	 	[***]
	 	 	 	 	[***]	 	[***]	 	[***]



 






    - 7 -


     


    

 


5.3 Certain
Terms relating to Milestone Payments.


 


(a) Total
Milestone Payments. Each of the foregoing milestone payments shall be paid [***] by Tango or any of its Affiliates or Sublicensees.
In no event shall: [***].


 


(b) Valid
Claim Coverage. For any of the milestone events [***].


 


5.4 Royalty
Payments.


 


(a) Royalty
Rate. During the applicable Royalty Term, Tango shall pay to Medivir royalties on Net Sales of Licensed Products at the applicable
rate set out below:


 



	Annual Net Sales of Licensed Products	 	Royalty Rate
	Portion of Annual Net Sales of Licensed Products up to and including [***]	 	[***]
	Portion of Annual Net Sales of Licensed Products in excess of [***]	 	[***]




 


(b) Certain
Terms relating to Royalty Payments.


 


(i) Valid
Claim Coverage. If a Licensed Product is not covered by a Valid Claim of a Licensed Patent or a Valid Claim of a Tango Patent in
the country in which such Licensed Product is sold, the royalty payable by Tango with respect to such Licensed Product in such country
shall be reduced by [***] of the amount otherwise payable pursuant to this Section 5.4.


 






    - 8 -


     


    

 


(ii) Third
Party Payments. If Tango, its Affiliate or Sublicensee becomes obligated to pay amounts to one or more Third Parties to obtain a
license under any such Third Party’s Patents, information, data, materials, know-how or other intellectual property rights covering
a Licensed Product, Tango may deduct [***] of the amount payable to such Third Party from the amounts payable to Medivir pursuant to
this Article 5; provided that, no amount payable to Medivir pursuant to this Article 5 will be so reduced as a result of such deduction
to less than [***] of the amount that would otherwise be payable to Medivir pursuant to this Article 5.


 


(iii) Generic
Competition. On a Licensed Product-by-Licensed Product and country-by-country basis, if one or more Generic Versions of such Licensed
Product is launched in such country the amount payable to Medivir pursuant to this Section 5.4 shall be further reduced as follows: (x)
[***] in which Net Sales of such Licensed Product are less than [***] of the Net Sales of such Licensed Product in such country in the
[***] Tango’s royalty payment obligations for Net Sales of such Licensed Product in such country shall be reduced by [***] for
the remainder of the applicable Royalty Term and (y) subject to the preceding clause (x), in the [***] in which such Generic Version(s)
represent [***] of such Licensed Product in such country for such [***] , the applicable Royalty Term for such Licensed Product shall
be suspended in such country until such time as the [***]; provided that (A) no suspension pursuant to this clause (y) shall extend the
Royalty Term for any Licensed Product and (B) Tango shall have no obligation to pay any amounts that would have been due pursuant to
this Section 5.4 during such suspension. As used in this Section 5.4(b)(iii), [***].


 


(iv) [***].


 


(c) Royalty
Term. Tango’s obligation to pay royalties under this Section 5.4 shall continue on a Licensed Product-by-Licensed Product and
country-by-country basis, during the period beginning on the date of the First Commercial Sale of such Licensed Product in a country
and ending on the later of (a) [***] (the “Royalty Term”). Upon the expiration of the Royalty Term with respect to
a particular Licensed Product in a particular country, the licenses and rights granted by Medivir to Tango under this Agreement with
respect to such Licensed Product (and the Compound(s) included therein) in such country will become fully paid-up, royalty-free, perpetual
and irrevocable.


 


5.5 Net
Receipts. During the applicable Royalty Term for a Licensed Product, the Parties will share Net Receipts with respect to such Licensed
Product on a [***] basis, as follows: [***].


 


Article
VI

REPORTS AND PAYMENT TERMS


 


6.1 Milestone
Reports and Payments. Tango shall notify Medivir in writing within [***] of Tango becoming aware of the achievement of each milestone
event in Section 5.2 by Tango, its Affiliate or Sublicensee. After Medivir’s receipt of any such notice, Medivir shall submit an
invoice to Tango for the corresponding milestone payment. Tango shall pay such corresponding milestone payment within [***] after its
receipt of such invoice.


 






    - 9 -


     


    

 


6.2 Royalty
Reports and Payments Terms. Beginning with the [***] in which Tango or its Affiliate or Sublicensee makes a First Commercial Sale
of a Licensed Product to a Third Party, Tango shall furnish to Medivir a written report for such [***] and each [***] during the term
of this Agreement showing, on a country-by-country basis:


 


(a) the
gross sales of all Licensed Products sold by Tango, its Affiliates and Sublicensees during [***] and the calculation of Net Sales of
the Licensed Products from such gross sales;


 


(b) the
royalties, payable in United States Dollars, which shall have accrued under this Agreement based upon such Net Sales of the Licensed
Products;


 


(c) the
exchange rates used in determining the amount of royalties payable in United States Dollars, as more specifically provided in Section
6.3;


 


(d) Net
Receipts received by Tango, its Affiliates and Sublicensees during [***] and the calculation of Medivir’s share of such Net Receipts;
and


 


(e) the
aggregate reductions to or deductions from such payments in accordance with this Agreement; provided that Tango will report the aggregate
reductions to or deductions from such [***] of Section 1.27 herein only for [***].


 


Reports
to be provided by Tango to Medivir under this Section 6.2 shall be due [***] after the end of each such calendar quarter during the term
of this Agreement. Notwithstanding Section 1.27 above, if Tango receives royalties from a Sublicensee based upon Net Sales of Licensed
Products, then Tango may elect to substitute the definition of Net Sales from its agreement with such Sublicensee for the definition
of Net Sales hereunder for the purposes of calculating royalties due to Medivir on the Net Sales of Licensed Products by or under the
authority of such Sublicensee. Royalties and Net Receipts shown to have accrued by each report provided pursuant to Section 6.2 shall
be due and payable within [***] after the date such report is due.


 


6.3 Payment
Currency / Exchange Rate. All payments to be made under this Agreement shall be made in United States Dollars. If any currency conversion
is required in connection with the calculation of amounts payable hereunder, such conversion shall be made at a rate of exchange which
corresponds to the noon buying rate as published in The Wall Street Journal, U.S. Internet Edition, on the second to last business day
of the applicable calendar quarter for which such payment is due (or such other publication as agreed-upon by the Parties).


 


6.4 Exchange
Control. If at any time legal restrictions prevent the prompt remittance of royalties or other amounts with respect to any country
where Licensed Products are sold, Tango shall have the right, at its option, to make such payments by depositing, or causing to be deposited,
the amount of such payments in local currency to Medivir’s account in a bank or other depository designated by Medivir in such
country.


 






    - 10 -


     


    

 


6.5 Taxes.
Notwithstanding any other provision of this Agreement, Tango shall be entitled to deduct and withhold from any payments such amounts
as it is required to deduct and withhold pursuant to any tax laws of any jurisdiction or any regulation of any taxing authority thereof.
To the extent such amounts are deducted, withheld and paid by or on behalf of Tango to the appropriate taxing authority, such amounts
shall be treated for all purposes of this Agreement as having been paid to Medivir. Tango shall provide Medivir with official receipts
issued by the appropriate governmental agency or such other evidence as is reasonably requested by Medivir to establish that such taxes
have been paid. Each Party shall provide to the other Party with such assistance as may be reasonably requested in connection with any
application to qualify for the benefit of a reduced rate of withholding taxation, under the terms of any income tax treaty between the
United States and other jurisdictions.


 


6.6 Records.
Tango shall keep, and shall require that its Affiliates and Sublicensees keep, complete and accurate books of account and records in
sufficient detail to enable the amounts payable under this Agreement to be determined. Such books and records shall be kept at the principal
place of business of Tango, its Affiliate or Sublicensee, as the case may be, for at least [***] following the end of the calendar year
to which such books and records pertain.


 


6.7 Audits.


 


(a) Audit
Rights. Upon at least [***] prior written notice from Medivir, Tango shall permit, and shall require its Affiliates and use reasonable
efforts to require its Sublicensees, to permit, an independent certified public accounting firm of nationally recognized standing, selected
by Medivir and reasonably acceptable to Tango, to have access during normal business hours to such books of account and records of Tango,
and its Affiliates and Sublicensees, at such Person’s principal place of business, solely to verify the accuracy of the reports
provided by Tango pursuant to Section 6.2. Such audits may not (i) be conducted for any calendar year ending more than [***] prior to
the date of such request, (ii) be conducted more than once in any calendar year or (iii) be repeated for any calendar quarter.


 


(b) Audit
Results. Medivir shall require the independent accountant to provide to Tango an audit report containing its conclusions regarding
any audit, and specifying whether the amounts paid were correct or, if incorrect, the amount of any underpayment or overpayment. The
independent accountant shall provide to Tango a preliminary copy of its audit report, and shall discuss with Tango any issues or discrepancies
that Tango identifies, prior to submission to Medivir. The independent accountant will disclose to Medivir only whether the payments
subject to such audit are correct or incorrect and the specific details concerning any discrepancies. No other information will be provided
to Medivir without the prior consent of Tango unless disclosure is required by applicable laws or judicial order. If such audit establishes
that additional royalties were owed to Medivir during the period covered by any audit conducted pursuant to Section 6.7(a), Tango shall
remit to Medivir within [***] after the date on which Medivir delivers to Tango such accounting firm’s written report so concluding
the amount of such additional royalties. In the event such audit establishes that amounts were overpaid by Tango during such period,
the amount of such overpayment shall promptly be refunded to Tango. The fees charged by such accounting firm in connection with any audit
pursuant to this Section 6.7 shall be paid by Medivir; provided, however, that if a discrepancy in favor of Medivir of more than [***]
of the aggregate amount of payments due hereunder for the period being audited is established, then Tango shall pay the reasonable fees
and expenses charged by such accounting firm in connection with such audit.


 




    - 11 -


     


    

 


(c) Confidential
Financial Information; Other Matters. Medivir shall treat all financial information subject to review under this Article 6 as confidential,
and shall cause the independent accountant to retain all such financial information in confidence. In addition, Tango is entitled to
require the independent accountant to execute a reasonable confidentiality agreement prior to commencing any such audit. If Tango is
unable to obtain from any Sublicensee a right for Medivir to audit the books of account and records of such Sublicensee, Tango shall
obtain the right to inspect and audit such Sublicensee’s books and records for itself and shall exercise such audit rights on behalf
and at the expense of Medivir upon Medivir’s written request and disclose the results of any such audit to Medivir in accordance
with Section 6.7(b).


 


Article
VII

CONFIDENTIALITY


 


7.1 Proprietary
Information. Except as otherwise provided in this Article 7, during the term of this Agreement and for a period of [***] thereafter,
each Party (the “Recipient”) shall maintain in confidence and use only for purposes of this Agreement any confidential
information, data and materials supplied to such Party by the other Party (the “Disclosing Party”) under this Agreement;
provided that, unless the confidentiality of any information, data or material is expressly provided in this Agreement, if any such information,
data or materials are in tangible form, they are marked “Confidential” or “Proprietary,” or if disclosed orally,
they are identified as confidential or proprietary when disclosed and are confirmed in writing as confidential or proprietary within
[***] following such disclosure (such information, data and materials so disclosed, collectively “Proprietary Information”).
The obligations of the Recipient under this Article 7 not to disclose or use Proprietary Information received from the Disclosing Party
shall not apply, however, apply to the extent that any such information, data or materials:


 


(a) are
or become generally available to the public, or otherwise part of the public domain, other than by acts or omissions of the Recipient
in breach of this Agreement;


 


(b) are
disclosed to the Recipient, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing
Party not to disclose such information to others;


 


(c) were
already in the possession of the Recipient, other than under an obligation of confidentiality, prior to disclosure by the Disclosing
Party, as shown by Recipient’s written records existing prior to such disclosure; or


 


(d) are
subsequently and independently developed by the Recipient without use of or reference to the Proprietary Information of the Disclosing
Party, as shown by written records prepared contemporaneously with such disclosure.


 


It
is understood that the Licensed Know-How and the terms of this Agreement shall be deemed Proprietary Information of both Medivir and
Tango.


 






    - 12 -


     


    

 


7.2 Permitted
Disclosures. To the extent it is reasonably necessary or appropriate to fulfill its obligations or exercise its rights under this
Agreement or as otherwise permitted in this Agreement:


 


(a) a
Recipient may disclose Proprietary Information which it is otherwise obligated under this Article 7 not to disclose, to its Affiliates,
Sublicensees, assignees, contractors, existing and potential investors, collaborators and others on a need-to-know basis in accordance
with such Recipient’s exercise of its rights or performance of its obligations under this Agreement; provided that such persons
agree to be bound by obligations of confidentiality with respect to such Proprietary Information which are substantially similar in scope
and duration to those set forth in this Article 7; and


 


(b) a
Recipient may disclose Proprietary Information of the Disclosing Party to government or other regulatory authorities to the extent that
such disclosure is: (i) required by applicable law (including all applicable securities laws), regulation, agency or court order; or
(ii) is reasonably necessary in connection with the prosecution of any Patent, to obtain any authorization to conduct clinical studies,
or to obtain any Approval for a Licensed Product; provided that, in case of any disclosures required by law, the Recipient shall provide
reasonable advance notice to the Disclosing Party to allow such Party to oppose such disclosure or to request confidential treatment
of such Proprietary Information.


 


7.3 Terms
of Agreement. Each of the Parties agrees not to disclose to any Third Party the existence or the terms and conditions of this Agreement
without the prior consent of the other Party, except each Party may disclose the existence or the terms and conditions of this Agreement:
(a) to its advisors (including financial advisors, attorneys and accountants), potential and existing investors, collaboration partners
or acquirers, and others on a need to know basis, in each case under circumstances that reasonably protect the confidentiality thereof;
or (b) to the extent necessary to comply with applicable laws, rules or regulations, including securities laws, rules or regulations;
provided that, in the case of (b), above, the disclosing Party shall promptly notify the other Party and (other than in the case where
such disclosure is necessary, in the reasonable opinion of the disclosing Party’s outside legal counsel, to comply with securities
laws, rules or regulations) allow the other Party a reasonable opportunity to oppose with the body initiating the process and, to the
extent allowable by law, to seek limitations on the portion of the Agreement that is required to be disclosed. Each Party shall designate
a responsible corporate officer for the prompt review of proposed disclosures which the other Party is required to make to comply with
applicable laws, rules or regulations, including the rules of any recognized stock exchange.


 




    - 13 -


     


    

 


7.4 Publications;
Public Presentations. Tango and Medivir may each only publish, publicly present, or otherwise publicly disclose any information or
data within the Licensed Know-How in accordance with this Section 7.4. In the event Tango (or its Affiliate or Sublicensee) is the party
proposing to publish, publicly present, or otherwise publicly disclose information or data included in the Licensed Know-How, then, before
any such paper is submitted for publication or an oral presentation is made, Tango shall deliver a then-current copy of the paper or
materials for oral presentation to Medivir at least [***] prior to submitting the paper to a publisher or making such other presentation
or disclosure. Prior to the expiration of such [***] period, Medivir may request that Tango delete references to Medivir’s Proprietary
Information (other than Licensed Know-How) in any such paper; provided that, with respect to oral presentation materials, abstracts and
the like, Medivir shall make reasonable efforts to expedite review of such materials and abstracts and to respond to Tango as soon as
practicable. Further, on Medivir’s reasonable request, Tango will withhold publication of any such paper or any presentation for
an additional [***] in order to permit Tango to file for appropriate Patent protection if Tango reasonably deems it necessary. Any publication
by Tango shall include recognition of the contributions of Medivir according to standard practice for assigning scientific credit, either
through authorship or acknowledgement, as may be appropriate. Neither Medivir nor any of its Affiliates shall publish, publicly present,
or otherwise publicly disclose any item included in the Licensed Know-How (including any such Licensed Know-How relating to the Target
or any Compounds or Licensed Products), or authorize or enable any Third Party to do so, unless Tango consents to such publication, public
presentation or other public disclosure. Notwithstanding this Section 7.4 above, the requirements of this Section 7.4 are subject to
the publication rights of Third Party investigators and collaborators under the agreements pursuant to which any Clinical Trial results
for a Licensed Product to be published were generated; provided that Tango shall use reasonable efforts to require such Third Party investigators
and collaborators to agree to the foregoing publication review process.


 


7.5 Prior
Agreements. This Agreement supersedes that certain Confidentiality Agreement executed between the parties dated 9 October 2019 (the
“Confidentiality Agreement”). All information exchanged between the Parties under the Confidentiality Agreement shall
be deemed to have been disclosed under this Agreement and shall be subject to the terms of this Article 7.


 


Article
VIII

INTELLECTUAL PROPERTY AND INFRINGEMENT


 


8.1 Ownership
of Inventions.


 


(a) General.
As between the Parties, title to all inventions and other intellectual property made solely by personnel of Tango in connection with
this Agreement shall be owned by Tango, and title to all inventions and other intellectual property made solely by personnel of Medivir
in connection with this Agreement shall be owned by Medivir. Title to all inventions and other intellectual property made jointly by
personnel of Tango and Medivir in connection with this Agreement shall be jointly owned by the Parties.


 


(b) Jointly-Owned
Intellectual Property. Except as expressly provided in this Agreement, it is understood that neither Party shall have any obligation
to account to the other for profits, or to obtain any approval of the other Party to license, assign or otherwise exploit such jointly-owned
inventions or intellectual property, by reason of joint inventorship thereof, and each Party hereby waives any right it may have under
the laws of any jurisdiction to require any such approval or accounting; provided, however, that any license, assignment or exploitation
by Medivir or any of its Affiliates of its or their interest in any jointly-owned invention or intellectual property shall be subject
to the license and rights granted to Tango, and the obligations of Medivir, under Article 2.


 




    - 14 -


     


    

 


8.2 Patent
Prosecution and Maintenance.


 


(a) By
Tango. Tango shall have the right, at its expense, to control the preparation, filing, prosecution and maintenance of the Patents
included in the Licensed Patents. Tango shall consult with Medivir in good faith regarding such filing, prosecution and maintenance of
the Licensed Patents. As used in this Section 8.2, “prosecution” shall include interferences, re-examinations, reissues,
oppositions, obtaining certificates of correction, patent term extensions and similar supplemental protections.


 


(b) By
Medivir. If Tango determines to not to continue the prosecution or maintenance of any Patent within the Licensed Patents, other than
in the case of a determination to abandon a patent application within the Licensed Patents for purposes of re-filing a replacement application,
then Tango shall provide Medivir with at least [***] written notice of such decision, or if less than [***] notice, as long as reasonably
practicable, prior to the next applicable filing, submission or payment date for such Patent. In such event, Medivir shall have the right,
at its option and expense, to control the preparation, filing, prosecution and maintenance of such Patent. Medivir shall consult with
Tango in good faith regarding the filing, prosecution and maintenance of any Licensed Patent assumed by Medivir pursuant to this Section
8.2(b).


 


(c) Cooperation.
Each Party shall cooperate with the other Party in connection with activities relating to the preparation, filing, prosecution and maintenance,
including abandonment, of the Licensed Patents undertaken by the other Party pursuant to this Section 8.2, including: (i) making available
to such other Party in a timely manner any documents or information reasonably necessary or appropriate to facilitate such other Party’s
filing, prosecution, maintenance or abandonment of any Licensed Patent; and (ii) if and as appropriate, signing (or causing to have signed)
all documents relating to the filing, prosecution, maintenance or abandonment of any Licensed Patent by such other Party. Each Party
shall also promptly provide to the other Party all information reasonably requested by such other Party with regard to such Party’s
activities pursuant to this Section 8.2. To the extent that the Parties agree that, in order to overcome a rejection or otherwise, the
filing of a terminal disclaimer with respect to a Licensed Patent is required or advisable, then Medivir shall assign to Tango the Licensed
Patent subject to such terminal disclaimer. All communications between the Parties relating to the preparation, filing, prosecution or
maintenance of the Licensed Patents, including copies of any draft or final documents or any communications received from or sent to
patent offices or patenting authorities with respect to such Patents, shall be considered the Confidential Information of both Parties,
subject to Article 7.


 


8.3 Enforcement.


 


(a) Notice.
In the event either Party learns of any infringement of the Licensed Patents by the manufacture, use, sale, offer for sale or importation
of any product (an “Infringement”), it shall promptly provide written notice to the other Party of such Infringement
and shall supply such other Party with all evidence it possesses pertaining to such Infringement.


 


(b) Infringement
Action. Tango (directly or through its nominee) shall have the first right, but not the obligation, to seek to abate any Infringement,
or to file suit against an infringing party. In the event that Tango or its nominee does not, within [***] from date of a request by
Medivir to do so, take action to abate such Infringement, then Medivir shall have the right, but not the obligation, to enforce the Licensed
Patents in connection with such Infringement in its own name, and at its own cost and expense.


 






    - 15 -


     


    

 


(c) Cooperation.
In any suit, action or other proceeding in connection with an Infringement (an “Infringement Action”), the Party assuming
the primary role in the Infringement Action (“Controlling Party”) shall keep non-Controlling Party reasonably informed
of the progress of such Infringement Action. The non-Controlling Party shall cooperate fully with the Controlling Party, including by
joining as a nominal party and executing such documents as the Controlling Party may reasonably request. In any case, the non-Controlling
Party shall have the right, even if not required to be joined, to participate in any Infringement Action with counsel of its own choice
at its own expense.


 


(d) Costs
and Recoveries. The Controlling Party with respect to any Infringement Action may not settle any such action, or otherwise consent
to any adverse judgment in any such action, that restricts the scope of, or admits the unenforceability or invalidity of, any Licensed
Patent without the express written consent of the non-Controlling Party, which consent shall not be unreasonably withheld. The costs
and expenses of an Infringement Action shall be the responsibility of the Controlling Party, and any damages or other monetary awards
received by the Controlling Party shall first be applied to reimburse the Controlling Party’s out-of-pocket costs and expenses
attributed to the Infringement Action, and the remainder shall be shared as follows: [***] to Tango; and [***] to Medivir; provided that
the share paid to or retained by Medivir shall not exceed [***]. For the avoidance of doubt, neither Party shall be obligated to share
any Net Receipts other than as contemplated by Section 5.5.


 


8.4 Defense
of Infringement Claims. If any Licensed Product manufactured, used or sold by Tango, its Affiliates, or Sublicensees, becomes the
subject of a Third Party’s claim or assertion of infringement of a Patent relating to the manufacture, use, sale, offer for sale
or importation of such Licensed Product, the Party first having notice of the claim or assertion shall promptly notify the other Party,
and the Parties shall promptly confer to consider the claim or assertion and the appropriate course of action. Unless the Parties otherwise
agree in writing, each Party shall have the right to defend itself against a suit that names such Party as a defendant. In any event,
each Party shall reasonably assist the other Party and cooperate in connection with any litigation in which such Party is not named as
a defendant, at the defending Party’s request and expense. [***]


 


Article
IX

TERM AND TERMINATION


 


9.1 Term.
This Agreement shall commence on the Effective Date and, unless terminated earlier pursuant to Section 9.2 or Section 9.3, shall continue
in full force and effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the Royalty Term
with respect to such Licensed Product in such country. For clarity, upon expiration of the last-to-expire Royalty Term, this Agreement
shall expire in its entirety, and all licenses and rights granted by Medivir to Tango under this Agreement will become fully paid-up,
royalty-free, perpetual and irrevocable.


 






    - 16 -


     


    

 


9.2 Termination
for Material Breach. If either Party materially breaches this Agreement at any time, the non-breaching Party shall have the right
to terminate this Agreement by written notice to the breaching Party, if such material breach is not cured within [***] after written
notice is given by the non-breaching Party to the breaching Party specifying the breach, subject to Section 12.6 below.


 


9.3 Termination
by Tango. This Agreement may be terminated by Tango, in its sole discretion, upon [***] written notice to Medivir, provided that
if a Licensed Product has achieved First Commercial Sale in any country of the Territory, and Tango’s termination is not based
on patient safety concerns with, or a risk of infringement or misappropriation of Third Party intellectual property rights relating to,
the Licensed Product, then Tango shall provide [***] written notice.


 


9.4 Effect
of Expiration or Termination.


 


(a) Termination
for Cause by Medivir or Termination by Tango. Upon termination of this Agreement by Medivir in accordance with Section 9.2 or termination
of this Agreement by Tango in accordance with Section 9.3:


 


(i) the
licenses and rights granted by Medivir to Tango under Article 2 will immediately terminate; and


 


(ii) notwithstanding
the foregoing, any sublicenses granted to a Sublicensee prior to the effective date of termination of this Agreement pursuant to Section
9.2 shall survive if the relevant Sublicensee agrees in writing to be bound by the terms of this Agreement as such terms apply to such
Sublicensee (in which event, such Sublicensee will be deemed a direct licensee of Medivir); provided, further, that any such Sublicensee
shall only be responsible for any payments that become due as a result solely of such Sublicensee’s activities after the effective
date of any such termination. For clarity, Sublicensees who agree to be bound by the terms of this Agreement pursuant to this Section
9.4(a)(ii) will not be responsible for any milestone payments already paid by Tango prior to the effective date of any such termination,
nor any milestone payments that may accrue as a result of the activities of any other Sublicensee after the effective date of any such
termination of this Agreement.


 


(b) Termination
for Cause by Tango. Upon termination of this Agreement by Tango in accordance with Section 9.2, without limiting any other remedies
available, the licenses and rights granted by Medivir to Tango under Article 2 shall survive, subject to the due payment by Tango of
any payments set out in Section 5.2, Section 5.4 or Section 5.5 provided, that the amount of any payments set out in Section 5.2, Section
5.4 or Section 5.5 shall be reduced by [***], however, following such termination, in no case shall the royalty due to Medivir under
Section 5.4 be less than [***] irrespective of how many deductions are due under Section 5.4(b) and this Section 9.4(b). In addition,
without limiting the foregoing or Tango’s ability to recover damages hereunder, up to [***] of such payments in each calendar year
may be retained by Tango and offset against any award of damages to Tango ruled in arbitration proceedings pursuant to Section 12.6(b).


 




    - 17 -


     


    

 


 


9.5 Right
of First Negotiation for Candidate Drugs.


 


(a) Certain
Terminations. In the event of a termination of this Agreement by Medivir in accordance with Section 9.2 or termination of this Agreement
by Tango in accordance with Section 9.3, in each case that occurs after at least one Compound is a Candidate Drug, Medivir’s right
of first negotiation to obtain a License as set forth in this Section 9.5 (the “ROFN”) shall apply. If, upon such
termination, Medivir wishes to negotiate with Tango to obtain a right or license to develop or commercialize such Candidate Drug(s) (a
“License”), then Medivir shall so notify Tango in writing (the “Negotiation Notice”) within [***]
after the first to occur of (a) the effective date of such termination pursuant to Section 9.2 or (b) the date of notice of such termination
pursuant to Section 9.3 (the “Notice Period”). If Tango receives the Negotiation Notice within the Notice Period,
then Tango shall negotiate with Medivir the terms and conditions of such License for a period of up to [***] after the date of such Negotiation
Notice from Medivir (the “Negotiation Period”).


 


(b) Divestiture
Determination. If, after at least one Compound is a Candidate Drug, Tango makes a determination not to conduct, either directly or
with or through an Affiliate or with a Third Party, any activities in support of the development or commercialization of any compound
or product Directed To the Target and to divest such Candidate Drug(s) (the “Divestiture Determination”), then Medivir’s
ROFN under this Section 9.5 shall also apply, subject to the following adjustments: [***]


 


(c) If
Medivir does not provide a Negotiation Notice within the applicable Notice Period or the Parties fail to reach agreement on the terms
and conditions of such License within the Negotiation Period, then Medivir shall have no further rights, and Tango shall have no further
obligations, under this Section 9.5. Notwithstanding the foregoing, Medivir’s rights pursuant to this Section 9.5 shall be subject
to any then- outstanding rights of any Sublicensee or other Third Party with which Tango has an agreement to conduct joint research and
development activities.


 


9.6 Survival
of Certain Obligations. Subject to Section 9.4, expiration or termination of this Agreement for any reason shall not relieve either
Party of any obligation accruing on or prior to such expiration or termination, or which is attributable to a period prior to such expiration
or termination, nor preclude either Party from pursuing any rights and remedies it may have under this Agreement, or at law or in equity,
which accrued or are based upon any event occurring prior to such expiration or termination. The provisions of Articles 1, 7, 11 and
12 and of Sections 6.5, 6.6, 6.7, 8.1, 9.1, 9.4, 9.6, 9.7 and 10.3 shall survive the expiration or termination of this Agreement for
any reason.


 


9.7 Damages;
Relief. Termination of this Agreement shall not preclude either Party from claiming any other damages, compensation or relief to
which it may be entitled upon such termination.


 




    - 18 -


     


    

 


Article
X

REPRESENTATIONS AND WARRANTIES


 


10.1 General
Representations and Warranties. Each Party represents and warrants to the other Party that:


 


(a) it
is a corporation duly organized and validly existing under the laws of the jurisdiction in which it is incorporated;


 


(b) it
has full corporate power and authority, and has obtained all approvals, permits and consents necessary, to enter into this Agreement
and to perform its obligations hereunder;


 


(c) this
Agreement is legally binding upon it and enforceable in accordance with its terms; and


 


(d) the
execution, delivery and performance of this Agreement does not conflict with any agreement, instrument or understanding, oral or written,
to which it is a party or by which it may be bound, nor violate any material law or regulation of any governmental or regulatory authority
having jurisdiction over it.


 


10.2 Additional
Warranties of Medivir. Medivir hereby covenants, represents and warrants to Tango that:


 


(a) Medivir
owns all right, title and interest in and to the Patents and other items listed on Exhibits 1.21 and 1.22, and as of the Effective Date,
the Patents listed in Exhibit 1.22 are the only Patents that are owned or Controlled by Medivir or any of its Affiliates, or in which
Medivir or any of its Affiliates has any rights, that are necessary to research, develop, manufacture, use or otherwise commercialize
Licensed Products;


 


(b) to
Medivir’s knowledge as of the Effective Date, the patent applications within the Licensed Patents define novel and patentable subject
matter within the context of a hit-to-lead (fast follower) program based on published Third Party leads;


 


(c) Neither
Medivir nor any of its Affiliates has any rights in any technology related to the Target or any Compound or Licensed Product that are
not Controlled by Medivir;


 


(d) Neither
Medivir nor any of its Affiliates has granted, nor will, during the term of this Agreement, grant any rights in the Licensed Intellectual
Property that conflict or are inconsistent with the rights granted to Tango under this Agreement or that would otherwise prevent Tango
from exercising its rights or performing its obligations under this Agreement on an exclusive basis; and Medivir has not received any
notice alleging any of the foregoing prior to the Effective Date;


 


(e) to
Medivir’s knowledge, the activities conducted with respect to the development, manufacture, use or other exploitation of the Compounds
prior to the Effective Date, including the generation of the Licensed Know-How existing as of the Effective Date, has not infringed or
otherwise conflicted with, or constituted the misappropriation of, any intellectual property rights or other rights of any Third Party;


 


(f) Medivir
is not aware of any infringement of any Licensed Patent or misappropriation of any Licensed Know-How by any Third Party;


 






    - 19 -


     


    

 


(g) as
of the Effective Date, the Licensed Intellectual Property is free and clear of all liens, claims, security interests or other encumbrances
of any kind, and neither Medivir nor any of its Affiliates shall permit the Licensed Intellectual Property to be encumbered by any liens,
claims, security interests or other encumbrances of any kind during the term of the Agreement;


 


(h) (i)
all Inventions (as defined below) are deemed the property of Medivir under the Law on Employee Inventions 1949, which casts an obligation
on designated inventors to assign all right, title and interest in and to their inventions and other information, data, materials, know-how
and other subject matter, whether or not patentable, and all intellectual property rights in and to the foregoing (collectively, “Inventions”),
to Medivir as the sole owner thereof; (ii) all employees and consultants of Medivir and its Affiliates performing activities relating
to the Compounds, or otherwise involved in the generation of the Licensed Know-How or any inventions covered by the Licensed Patents,
have assigned (or confirmed the assignment of) all right, title and interest in and to their Inventions to Medivir as the sole owner
thereof, pursuant to a written agreement; and (iii) Medivir has paid each respective inventor premiums pursuant to the Law on Employee
Inventions and retains future inventor payment obligations, for which Medivir remains solely liable; and


 


(i) To
the extent that Medivir’s screening and fragment libraries were screened for activity Directed To the Target prior to the Effective
Date, the results of such screening, including any structure activity relationship conclusions therefrom, were incorporated into the
Target research program and, for the avoidance of doubt, constitute Licensed Know-How. As of the Effective Date Medivir has no reason
to believe that further interrogation of those libraries will aid further elucidation of the Target; and


 


(j) Medivir
and its Affiliates have not, up through and including the Effective Date, intentionally or recklessly omitted to furnish Tango with any
information in its or any of its Affiliate’s Control or possession or of which it is aware, concerning: (i) the Licensed Patents;
(ii) the Licensed Know-How; (iii) the development, manufacture, sale or other commercialization of any Compound or Licensed Product;
or (iv) the activities contemplated by this Agreement, in each case, which is reasonably likely to be material to Tango’s decision
to enter into this Agreement and to undertake the commitments and obligations set forth herein.


 


10.3 DISCLAIMER.
EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND
EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR VALIDITY OF
ANY PATENTS ISSUED OR PENDING.


 




    - 20 -


     


    

 


Article
XI

INDEMNIFICATION


 


11.1 Indemnification
by Tango. Tango shall defend, indemnify, and hold harmless Medivir, its Affiliates and their respective directors, officers, shareholders,
employees and agents (“Medivir Indemnitees”), from and against any and all liabilities, claims, damages, losses, costs
and expenses (including reasonable attorney’s fees) owing to Third Parties (collectively, “Liabilities”) suffered
or sustained by a Medivir Indemnitee, or to which a Medivir Indemnitee becomes subject, to the extent arising out of or attributable
to: (a) any breach of a representation, warranty, covenant or agreement made or undertaken by Tango under this Agreement; or (b) the
development, manufacture, use, offer for sale, sale or marketing of a Licensed Product by Tango, its Affiliates or Sublicensees. However,
Tango shall not indemnify or hold harmless any Medivir Indemnitee from any Liabilities to the extent that such Liabilities resulted from
the acts or omissions of a Medivir Indemnitee.


 


11.2 Indemnification
by Medivir. Medivir shall defend, indemnify, and hold harmless Tango, its Affiliates and their respective directors, officers, shareholders,
employees and agents (“Tango Indemnitees”), from and against any and all Liabilities suffered or sustained by a Tango
Indemnitee, or to which a Tango Indemnitee becomes subject, to the extent arising out of or attributable to: (a) any breach of a representation,
warranty, covenant or agreement made or undertaken by Medivir under this Agreement; or (b) the research, development, use, transfer,
manufacture or other exploitation of any Compound or Licensed Product by Medivir, its Affiliates or any Third Party under authority of
Medivir. However, Medivir shall not indemnify or hold harmless any Tango Indemnitee from any Liabilities to the extent that such Liabilities
resulted from the acts or omissions of a Tango Indemnitee.


 


11.3 Indemnification
Procedures. In the event that a Tango Indemnitee or a Medivir Indemnitee (each, an “Indemnitee”) intends to claim
indemnification under this Article 11, such Indemnitee shall promptly notify the other Party in writing of the alleged Liability. The
indemnifying Party shall have the right to control the defense thereof with counsel of its choice as long as such counsel is reasonably
acceptable to the Indemnitee; provided, however, that any Indemnitee shall have the right to retain its own counsel at its own expense,
for any reason, including if representation of any Indemnitee by the counsel retained by the indemnifying Party would be inappropriate
due to actual or potential differing interests between such Indemnitee and any other Person reasonably represented by such counsel in
such proceeding. The affected Indemnitee shall cooperate with the indemnifying Party and its legal representatives in the investigation
of any Liability covered by this Article 11. The Indemnitee shall not, except at its own cost, voluntarily make any payment or incur
any expense with respect to any claim or suit without the prior written consent of the indemnifying Party, which such Party shall not
be required to give.


 


Article
XII

MISCELLANEOUS


 


12.1 Force
Majeure. Neither Party shall be held liable or responsible to the other Party, nor be deemed to have defaulted under or breached
this Agreement, for failure or delay in fulfilling or performing any term of this Agreement to the extent, and for so long as, such failure
or delay is caused by or results from causes beyond the reasonable control of the affected Party, including fire, floods, embargoes,
power shortage or failure, acts of war (whether war be declared or not), insurrections, riots, terrorism, civil commotions, strikes,
lockouts or other labor disturbances, acts of God or any acts, omissions or delays in acting by any governmental authority or the other
Party.


 






    - 21 -


     


    

 


12.2 Assignment.
Either Party may assign or transfer this Agreement: (a) without the consent of the other Party, (i) to an Affiliate or (ii) in connection
with the transfer or sale of all or substantially all of its assets or business related to this Agreement, or in the event of its merger,
consolidation or similar transaction; and (b) in any other circumstance, only with the prior written consent of the other Party. Medivir
shall not assign or otherwise transfer to any Affiliate or any Third Party any ownership interest in or to any Licensed Intellectual
Property, unless such Affiliate or Third Party agrees to be bound by all of the terms and conditions of this Agreement. Any permitted
assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment by a Party in violation of this
Agreement shall be void.


 


12.3 Severability.
If one (1) or more provisions of this Agreement is held to be invalid, illegal or unenforceable, the Parties shall substitute, by mutual
consent, valid provisions for such invalid, illegal or unenforceable provisions which valid provisions are, in their economic effect,
sufficiently similar to the invalid provisions that it can be reasonably assumed that the Parties would have entered into this Agreement
with such provisions. In the event that such provisions cannot be agreed upon, the invalidity, illegality or unenforceability of one
(1) or more provisions of the Agreement shall not affect the validity of this Agreement as a whole, unless the invalid provisions are
of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this
Agreement without such invalid provisions.


 


12.4 Notices.
Any notice, consent or report required or permitted to be given or made under this Agreement by one Party to the other Party shall be
in English and in writing, delivered personally or by facsimile (receipt verified and a copy promptly sent by personal delivery, U.S.
first class mail or express courier providing evidence of receipt, postage prepaid (where applicable)), or by U.S. first class mail or
express courier providing evidence of receipt, postage prepaid (where applicable), at the following address for a Party (or such other
address for a Party as may be specified by like notice):


 


If
to Medivir, to:


 


Medivir
AB

Courier: Lunastigen 7, SE-141 44 Huddinge Sweden


 


Attention:
CEO


 


If
to Tango, to:


 


Tango
Therapeutics, Inc.

100 Binney Street, Suite 700

Cambridge, MA 02142

Attention: Chief Executive Officer


 


with
a copy (which shall not constitute notice) to:


 


Wilson
Sonsini Goodrich & Rosati

28 State Street

Boston, MA 02109

Attention: Farah B. Gerdes, Esq.


 


All
such notices, consents or reports shall be effective upon receipt.


 






    - 22 -


     


    

 


12.5 Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of England, without regard to the conflicts of
law principles thereof.


 


12.6 Dispute
Resolution.


 


(a) Referral
to Senior Management. The Parties agree to attempt initially to solve any dispute, claim or controversy arising under, out of, or
in connection with this Agreement (a “Dispute”) by conducting good faith negotiations. Any Dispute which cannot be
resolved by good faith negotiation within [***] (or as otherwise specified in this Agreement), shall be referred, by written notice from
either Party to the other, to the Chief Executive Officer, or authorized representative designated by the Chief Executive Officer, of
each Party. Such Chief Executive Officers (or their respective designees) shall negotiate in good faith to resolve such Dispute through
discussions promptly following such written notice, and in any event within [***] thereafter. If the Chief Executive Officers of the
Parties (or their respective designees) are unable to resolve the Dispute within [***], either Party may, by written notice to the other
Party, invoke the provisions of Section 12.6(b).


 


(b) Arbitration.


 


(i) Except
as otherwise expressly provided in this Section 12.6, the Parties agree that if they are unable to resolve, in accordance with Section
12.6(a) above, any Dispute as to the breach, performance or interpretation of this Agreement, such Dispute shall, upon written notice
of either Party to the other, be referred for resolution by final, binding arbitration in accordance with the provisions of this Section
12.6(b). The arbitration shall be conducted by the Judicial Arbitration and Mediation Services, Inc. (or any successor entity thereto)
(“JAMS”) under its rules of arbitration then in effect, except as modified in this Agreement. The arbitration shall
be conducted in the English language, by a single arbitrator. The arbitrator shall engage an independent expert with experience in the
subject matter of the Dispute to advise the arbitrator.


 


(ii) With
respect to any Dispute arising under this Agreement, the Parties and the arbitrator shall use all reasonable efforts to complete any
such arbitration within [***] from the issuance of notice of a referral of any such Dispute to arbitration. The arbitrator shall determine
what discovery will be permitted, consistent with the goal of limiting the cost and time which the Parties must expend for discovery;
provided that the arbitrator shall permit such discovery as he or she deems necessary to permit an equitable resolution of the Dispute.


 


(iii) The
Parties agree that the decision of the arbitrator shall be the sole, exclusive and binding remedy between them regarding the Dispute
presented to the arbitrator. Any decision of the arbitrator may be entered in a court of competent jurisdiction for judicial recognition
of the decision and an order of enforcement. The arbitration proceedings and the decision of the arbitrator shall not be made public
without the joint consent of the Parties and each Party shall maintain the confidentiality of such proceedings and decision unless each
Party otherwise agrees in writing; provided that either Party may make such disclosures as are permitted for Proprietary Information
of the other Party under Article 7 above.


 




    - 23 -


     


    

 


(iv) Unless
otherwise mutually agreed upon by the Parties, the arbitration proceedings shall be conducted in London, England. The Parties agree that
they shall share equally the cost of the arbitration filing and hearing fees, the cost of the independent expert retained by the arbitrator,
and the cost of the arbitrator and administrative fees of JAMS. Each Party shall bear its own costs and attorneys’ and witnesses’
fees and associated costs and expenses.


 


(c) Pending
the selection of the arbitrator or pending the arbitrator’s determination of the merits of any Dispute, either Party may seek appropriate
interim or provisional relief from any court of competent jurisdiction as necessary to protect the rights or property of that Party.
In addition, notwithstanding Section 9.2 above, if a Party alleged to be in breach of this Agreement or allegedly failing to engage in
material research, development, manufacture or commercialization activities disputes such breach or failure within the [***] period specified
in Section 9.2, this Agreement shall not be terminated unless an arbitrator determines in a written decision delivered to the Parties
under this Section 12.6(b) that this Agreement was materially breached or such party did fail to engage in material research, development,
manufacture or commercialization activities, and such Party fails to cure such breach or failure within [***] after such determination,
or if not curable during such period, within a reasonable period to be determined by the arbitrator.


 


12.7 LIMITATION
OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY PUNITIVE, SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES
ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY; PROVIDED HOWEVER THAT NOTHING IN THIS SECTION 12.7 SHALL
BE DEEMED TO LIMIT (A) MEDIVIR’S LIABILITY FOR BREACH OF SECTION 2.2 NOR (B) THE INDEMNIFICATION OBLIGATIONS OF EITHER PARTY UNDER
ARTICLE 11 TO THE EXTENT A THIRD PARTY RECOVERS ANY PUNITIVE, SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES FROM AN INDEMNITEE.


 


12.8 Entire
Agreement. This Agreement (including the Exhibits attached hereto) contains the entire agreement by the Parties with respect to the
subject matter hereof and supersedes any prior express or implied agreements, understandings and representations, either oral or written,
which may have related to the subject matter hereof in any way, including the Confidentiality Agreement.


 


12.9 Interpretation.
The captions to the several Articles and Sections of this Agreement are not a part of this Agreement, but are included for convenience
of reference and shall not affect its meaning or interpretation. In this Agreement: (a) the words “include” or “including”
shall be construed as incorporating, also, “but not limited to” or “without limitation;” (b) the word “day”
or “year” means a calendar day or year unless otherwise specified; (c) the word “notice” means notice in writing
(whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under
this Agreement; (d) the words “hereof,” “herein,” “hereby” and derivative or similar words refer
to this Agreement as a whole and not merely to the particular provision in which such words appear; (e) the words “shall”
and “will” have interchangeable meanings for purposes of this Agreement; (f) the word “or” shall have the inclusive
meaning commonly associated with “and/or”; (g) provisions that require that a Party, the Parties or a committee hereunder
“agree,” “consent” or “approve” or the like shall require that such agreement, consent or approval
be specific and in writing, whether by written agreement, letter, approved minutes or otherwise; (h) words of any gender include the
other gender; (i) words using the singular or plural number also include the plural or singular number, respectively; (j) references
to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments
thereto or any replacement law, rule or regulation thereof; (k) neither Party or its Affiliates shall be deemed to be acting “under
authority of” the other Party.


 






    - 24 -


     


    

 


12.10 Independent
Contractors. It is expressly agreed that Medivir and Tango shall be independent contractors and that the relationship between the
two Parties shall not constitute a partnership, joint venture or agency or other fiduciary relationship. Neither Medivir nor Tango shall
have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding
on the other Party, without the prior written consent of the other Party to do so.


 


12.11 Waiver;
Amendment. Except as otherwise expressly provided in this Agreement, any term of this Agreement may be waived only by a written instrument
executed by a duly authorized representative of the Party waiving compliance. The delay or failure of any Party at any time to require
performance of any provision of this Agreement shall in no manner affect such Party’s rights at a later time to enforce the same.
This Agreement may be amended, and any term of this Agreement may be modified, only by a written instrument executed by a duly authorized
representative of each Party.


 


12.12 Rights
in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement are intended to be, and shall otherwise be deemed
to be, licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code for purposes
of Section 365(n) of the United States Bankruptcy Code (the “Bankruptcy Code”) or any analogous provisions in any
other country or jurisdiction. The Parties agree that the licensee of such intellectual property under this Agreement shall retain and
may fully exercise all of its rights and elections under the Bankruptcy Code, or any analogous provisions in any other country or jurisdiction.
If a bankruptcy proceeding is commenced by or against either Party under the Bankruptcy Code or any analogous provisions in any other
country or jurisdiction, the non-debtor Party shall be entitled to a complete duplicate of (or complete access to, as appropriate) any
intellectual property licensed hereunder, and embodiments of such intellectual property, which, if not already in the non-debtor Party’s
possession, shall be delivered to the non-debtor Party within [***] of a request to do so; provided, that the debtor Party is excused
from its obligation to deliver such intellectual property to the extent the debtor Party continues to perform all of its obligations
under this Agreement and this Agreement has not been rejected pursuant to the Bankruptcy Code or any analogous provision in any other
country or jurisdiction.


 


12.13 Acquisition.
Notwithstanding any other provision of this Agreement, in the event of an Acquisition of Tango, no intellectual property, compounds,
products or other subject matter owned or controlled by the acquiring entity or any of its affiliates shall be subject to the terms or
conditions of this Agreement, including the payment obligations set forth in Article 5, so long as no Licensed Intellectual Property
is specifically used by, or disclosed in any material manner to, the acquiring entity for use with a compound or product Directed To
the Target. As used in this Section, “Acquisition” means: (i) a merger involving a Party, in which the shareholders
of such Party immediately prior to such merger cease to control (as defined in Section 1.1) such Party after such merger; (ii) a sale
of all or substantially all of the business or assets of a Party; or (iii) a sale of a controlling (as defined in Section 1.1) interest
of a Party.


 


12.14 Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Counterpart signature pages delivered by facsimile or similar electronic transmission (including
via e-mail in PDF format) shall be deemed binding as originals.


 


12.15 Binding
Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives,
successors and permitted assigns.


 


[Remainder
of page intentionally left blank; signature page follows]


 




    - 25 -


     


    

 


IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.


 


	TANGO THERAPEUTICS, INC.	 
	 	 
	BY:	/s/ Barbara Weber	 
	NAME:	Barbara Weber	 
	TITLE:	President and Chief Executive Officer	 
	 	 	 
	MEDIVIR AB	 
	 	 	 
	BY:	/s/ Uli Hacksell	 
	NAME:	Uli Hacksell	 
	TITLE:	CEO & President	 



 




    - 26 -


     


    

 


Exhibit
1.7

Compounds


 


[***]


 


	MV
Number (PCN)
	Parent
    Reg Date	Concat
    Notebook Page	Concat
    Distinct Lot ID	MV
    Number (PCN)	Parent
    Reg

 Date	Concat
    Notebook Page	Concat
    Distinct Lot ID
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]



 






    - 27 -


     


    

 


	MV
Number (PCN)
	Parent
    Reg Date	Concat
    Notebook Page	Concat
    Distinct Lot ID	MV
    Number (PCN)	Parent
    Reg

 Date	Concat
    Notebook Page	Concat
    Distinct Lot ID
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]



 



    - 28 -


     


    

 


	MV
Number (PCN)
	Parent
    Reg Date	Concat
    Notebook Page	Concat
    Distinct Lot ID	MV
    Number (PCN)	Parent
    Reg

 Date	Concat
    Notebook Page	Concat
    Distinct Lot ID
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]



 






    - 29 -


     


    

 


	MV
Number (PCN)
	Parent
    Reg Date	Concat
    Notebook Page	Concat
    Distinct Lot ID	MV
    Number (PCN)	Parent
    Reg

 Date	Concat
    Notebook Page	Concat
    Distinct Lot ID
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]



 






    - 30 -


     


    

 




	MV
Number (PCN)
	Parent
    Reg Date	Concat
    Notebook Page	Concat
    Distinct Lot ID	MV
    Number (PCN)	Parent
    Reg

 Date	Concat
    Notebook Page	Concat
    Distinct Lot ID
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]



 






    - 31 -


     


    

 


	MV
Number (PCN)
	Parent
    Reg Date	Concat
    Notebook Page	Concat
    Distinct Lot ID	MV
    Number (PCN)	Parent
    Reg

 Date	Concat
    Notebook Page	Concat
    Distinct Lot ID
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]



 






    - 32 -


     


    

 


	MV
Number (PCN)
	Parent
    Reg Date	Concat
    Notebook Page	Concat
    Distinct Lot ID	MV
    Number (PCN)	Parent
    Reg

 Date	Concat
    Notebook Page	Concat
    Distinct Lot ID
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]



 






    - 33 -


     


    

 


	MV
Number (PCN)
	Parent
    Reg Date	Concat
    Notebook Page	Concat
    Distinct Lot ID	MV
    Number (PCN)	Parent
    Reg

 Date	Concat
    Notebook Page	Concat
    Distinct Lot ID
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]


 




    - 34 -


     


    

 


Exhibit
1.21

Licensed Know-How


 


Files
in Data Room


 


	  
	Category	Subcategory	Number
    of files
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]


 


 




    - 35 -


     


    

 


Exhibit
1.22

Licensed Patents


 


	Medivir
ref.
	Application
    no.	Filing
    date	Comment
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]


 




    - 36 -


     


    

 


Exhibit
3.1(b)

A compound inventory is found in two files in the Data Room 


 


[***]


 


Reagents,
Substrates and Constructs 


 


	Plasmids
	Description	No
    of vials
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]



 






    - 37 -


     


    

 


	Plasmids
	Description	No
    of vials
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]


 


 


-
38 -